Comerț uniQure N.V. - QURE CFD

Condiții de tranzacționare

• Tip:
  CFD

  

  Knock-out

  
• Ecart minim: 0.11
• Ajustarea finanțării peste noapte a poziției lungi: -0.02157%
• Ajustarea finanțării peste noapte a poziției scurte: -0.00065%
• Oră ajustare finanțare peste noapte: 22:00 (UTC)
• Monedă: USD
• Cantitate minimă tranzacționată: 1
• Marjă: 50.00%
• Bursă: United States of America
• Comision tranzacționare: 0%
• Prima de oprire garantată: 1%

Statistici cheie

• Închis anterior: 24.47
• Deschidere: 27.28
• Schimbare la 1 an: 6.69%
• Interval zi: 25.23 - 27.28

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington''s disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer''s disease; and AMT-210 that is in preclinical trial to treat Parkinson''s disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.